Clinical Trial Success Rates Still Dismal, But Certain Sectors Outperform
The high risk-high reward nature of drug development is a constant challenge to pharma. Informa's Pharma Intelligence teamed up with BIO and Amplion to provide an update on clinical development success rates from 2006 to 2015, including a new analysis on trials incorporating patient selection biomarkers.
You may also be interested in...
Datamonitor Healthcare's recent review of R&D efficiency using new product launch success rates as a proxy shows that Mid Pharma companies outperform Big Pharma and Japan Pharma firms, thanks to multiple blockbuster drugs. The first in a two-part series evaluating R&D productivity.
Master protocols that allow for the simultaneous study of multiple agents will shave more time off in the clinic than one-off studies in small groups of patients, FDA’s Janet Woodcock predicted. The current timeframes in oncology development are “unacceptable,” and can be shortened, she said, by “doing things differently.”
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.